No one doubts the venture capital world is shrinking for life sciences.
But at least 345 venture stage biotechs around the world closed VC deals worth more than $6 billion last year. It was the second highest total in the past decade. And the total has not fallen below $5 billion in that time.
How has this happened? One answer: Corporate venture capital stepped in to fill the breach. This means big pharmaceutical and biotech companies are partnering with traditional VCs to invest in biotechs offering potential breakthrough technologies and products.
Can this ecosystem sustain the flow of innovation into the marketplace?
BioCentury speaks with:
|•||Kurt von Emster of the $200 million VenBio fund, which combines traditional limited partners with strategic investors like Amgen and Abbott.|
|•||Carole Nuechterlein, head of the $500 million Roche Venture Fund.|
NOTICE: BioCentury Publications, Inc., and WUSA-TV own the copyright to the program content on “BioCentury This Week,” and except for limited use of these links to the BioCenturytv.com website, BioCentury and WUSA prohibit hosting of BioCentury This Week program content by unauthorized third parties or posting of BioCentury This Week content to any unauthorized third party websites such as YouTube. Other BioCenturytv.com content and all trademarks are the property of BioCentury or WUSA-TV or other third parties.